BioCentury
ARTICLE | Company News

GeneCentric, Bristol-Myers Squibb deal

January 12, 2017 4:20 PM UTC

Bristol-Myers Squibb and GeneCentric partnered to explore the feasibility of using GeneCentric’s Cancer Subtype Platform (CSP) to identify translational biomarkers for cancer drug Opdivo nivolumab for...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article